Jan Scheele

Jürgen Scheele 3 collaborations

Josef Straub 2 collaborations

Rolf Bruns 2 collaborations

Thomas Decaens 1 collaboration

Carlo Barone 1 collaboration

Eric Assenat 1 collaboration

Martin Wermke 1 collaboration

Angelica Fasolo 1 collaboration

Philippe Merle 1 collaboration

Jean-Frédéric Blanc 1 collaboration

Véronique Grando 1 collaboration

Angelo Iacobellis 1 collaboration

Erica Villa 1 collaboration

Joerg Trojan 1 collaboration

Karin Berghoff 1 collaboration

Juergen Scheele 1 collaboration

Eric Raymond 1 collaboration

Sandrine Faivre 1 collaboration

Wojciech Jurczak 1 collaboration

Simon Rule 1 collaboration

William Townsend 1 collaboration

David Tucker 1 collaboration

Barbara Sarholz 1 collaboration

Martin Dyroff 1 collaboration

John G Gribben 1 collaboration

Monika Długosz-Danecka 1 collaboration

Pier Luigi Zinzani 1 collaboration

Ishita Mallick 1 collaboration

Pradnya Panchal 1 collaboration

Smita Kadam 1 collaboration

Priyanka Mohite 1 collaboration

Werner Seiz 1 collaboration

Amit Agarwal 1 collaboration

Om Prakash Sharma 1 collaboration

Yi-Long Wu 1 collaboration

Ying Cheng 1 collaboration

Jianying Zhou 1 collaboration

Shun Lu 1 collaboration

Yiping Zhang 1 collaboration

Jun Zhao 1 collaboration

Dong-Wan Kim 1 collaboration

Ross Andrew Soo 1 collaboration

Sang-We Kim 1 collaboration

Hongming Pan 1 collaboration

Yuh-Min Chen 1 collaboration

Chih-Feng Chian 1 collaboration

Xiaoqing Liu 1 collaboration

Daniel Shao Weng Tan 1 collaboration

Andreas Johne 1 collaboration

Keunchil Park 1 collaboration

James Chih-Hsin Yang 1 collaboration

None None 1 collaboration

H W Harmsen van der Vliet-Torij 1 collaboration

A A Venekamp 1 collaboration

H J M van Heijningen-Tousain 1 collaboration

E Wingelaar-Loomans 1 collaboration

J Scheele 1 collaboration

J P de Graaf 1 collaboration

M P Lambregtse-van den Berg 1 collaboration

E A P Steegers 1 collaboration

M J B M Goumans 1 collaboration

Publications (5)

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.

Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies.

In-silico identification and prioritization of therapeutic targets of asthma.

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.

Development of a Blueprint for Integrated Care for Vulnerable Pregnant Women.

Réseau de co-auteurs